Changes in bone density and microarchitecture following treatment of Graves' disease and the effects of vitamin D supplementation. A randomized clinical trial.

Plain-language guide to PMID 39264438 (2024): double-blind randomized controlled trial of Vitamin D, K2, Magnesium and Zinc.

Key Facts

PMID: 39264438
Journal: Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA
Year: 2024
Study type: Randomized Controlled Trial
Authors: Grove-Laugesen D et al. (5 authors)
DOI: 10.1007/s00198-024-07241-y
Registered trial: NCT02384668

What This Study Did, in Plain Language

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.

Vitamin D is important to skeletal health and ensuring a replete vitamin D status is recommended.

Why It Was Studied

Thyrotoxicosis leads to loss of bone mass.

Vitamin D is important to bone health.

Who Took Part

By PubMed's age tags, the people studied were young adults, adults and middle-aged adults, both men and women.

Effect of vitamin D versus placebo and the response to ATD treatment were analyzed using linear mixed modelling.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

The participants were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.

Blinding on both sides kept the participants and researchers unaware of who received Vitamin D, K2, Magnesium and Zinc.

A placebo (an inactive look-alike) gave the Vitamin D, K2, Magnesium and Zinc group a baseline to be compared against.

At baseline and 9 months, the researchers measured BMD and bone architecture using DXA and high resolution peripheral quantitative computerized tomography.

Bone turnover markers (BTM) were measured at 3 months also.

What Was Measured

Topics PubMed links to this paper include Graves Disease, Bone Density, Antithyroid Agents, Dietary Supplements, Cholecalciferol, Bone Remodeling and Absorptiometry, Photon.

Author keywords: Bone microarchitecture, Bone turnover markers, Graves’ disease, Thyrotoxicosis and Vitamin D.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2024 (Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.

Our Notes on the Compound

Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.

Vitamin D, K2, Magnesium and Zinc in the library

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.